Mounjaro

News

Lilly says tirzepatide staves off diabetes in phase 3 trial

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and ob

News

Lilly says tirzepatide supply issues are resolving

Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for startin

News

Lilly scores against Novo Nordisk in weight loss contest

There’s no data from a head-to-head trial directly comparing Eli Lilly and Novo Nordisk’s GLP-1 agonist drugs yet, but an observational study has found that Lilly’s tirzepatide seems to be

News

Scotland first UK nation to clear Mounjaro use for obesity

Scotland has become the first country in the UK to back NHS use of Eli Lilly’s obesity therapy Mounjaro, clearing it to assist weight management in eligible patients.

News

Lilly ups spend on diabetes, obesity drug production to $9bn

Eli Lilly is determined not to be left behind when it comes to manufacturing capacity for new diabetes and obesity therapies, raising its spending on a new plant in Indian

News

Britain will be first to get new Mounjaro device, says Lilly

Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment

Lilly says tirzepatide staves off diabetes in phase 3 trial

Lilly says tirzepatide supply issues are resolving

Lilly scores against Novo Nordisk in weight loss contest

Scotland first UK nation to clear Mounjaro use for obesity

Lilly ups spend on diabetes, obesity drug production to $9bn

Britain will be first to get new Mounjaro device, says Lilly

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Mounjaro

Editor's Picks